التفاصيل البيبلوغرافية
| العنوان: |
Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. |
| المؤلفون: |
Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, Mauro FR, Meloni G, ZINZANI, PIER LUIGI, TURA, SANTE |
| المساهمون: |
Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, Mauro FR, Meloni G, Zinzani PL, Tura S |
| سنة النشر: |
2006 |
| المجموعة: |
IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: |
Leukemia, Lymphocytic, Chronic, B-Cell | Patients | Therapeutics |
| الوصف: |
The Italian Society of Hematology (SIE) and two affiliate societies (SIES and GITMO) commissioned a project to develop clinical practice guidelines for the treatment of chronic lymphocytic leukemia (CLL). METHODS: Key questions in the management of patients with CLL were formulated by an Advisory Committee and approved by an Expert Panel of eight senior hematologists. After a systematic review of the literature, recommendations for disease-specific and supportive therapies were formulated and graded according to the supporting evidence. Explicit consensus methods were used for providing recommendations for questions with incomplete or potentially biased evidence. RESULTS: It is recommended that therapy is commenced in patients with CLL when at least one of the following are present: B-symptoms, progressive/obstructive lymphadenopathy or organomegaly, rapid lymphocyte doubling time, anemia or thrombocytopenia (of new onset, worsening or steroid-resistant). It is recommended that patients without co-morbidity should receive fludarabine plus cyclophosphamide, whereas elderly patients with co-morbidity should receive oral chlorambucil. Younger patients with unfavorable biological risk factors should be considered for high-dose chemotherapy and autologous or allogeneic stem cell transplantation within approved clinical trials. Patients either relapsing rapidly after, or non-responsive to, first-line chlorambucil should receive fludarabine-containing regimens. Patients either relapsing soon after or not responding to fludarabine-based chemotherapy should be considered for schedules including non-cross-reactive agents, such as alemtuzumab, possibly followed by high-dose chemotherapy and autologous transplantation in the context of a clinical trial or by allogeneic stem cell transplantation. CONCLUSIONS: We describe the results of a systematic literature review and an explicit approach to consensus techniques which resulted in recommendations for the key therapeutic decisions in patients with CLL. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
STAMPA |
| اللغة: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/17145603; info:eu-repo/semantics/altIdentifier/wos/WOS:000242809300011; volume:91; firstpage:1662; lastpage:1673; numberofpages:12; journal:HAEMATOLOGICA; http://hdl.handle.net/11585/33698; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-33845953927 |
| الاتاحة: |
http://hdl.handle.net/11585/33698 |
| Rights: |
info:eu-repo/semantics/openAccess |
| رقم الانضمام: |
edsbas.3BB55A11 |
| قاعدة البيانات: |
BASE |